Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001
暂无分享,去创建一个
R. Atkins | S. Chadban | K. Polkinghorne | P. Kerr | F. Chow
[1] M. Laville. [Hypertension in patients with chronic renal disease]. , 2004, La Revue du praticien.
[2] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[3] B. Kestenbaum,et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. , 2002, Kidney international.
[4] G. Block. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis) , 2001, Current opinion in nephrology and hypertension.
[5] T. Shoji,et al. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[6] A. Jardine,et al. Cardiovascular complications of renal disease , 2001, Heart.
[7] J. Bower,et al. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? , 2001, Clinical nephrology.
[8] A. Levin,et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] M. Pfeffer,et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. , 2000, American heart journal.
[10] M. Rocco,et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. , 2000, Kidney international.
[11] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[12] Panta Rhei. V. Clinical algorithms on cardiovascular risk factors in renal patients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[14] E. Lowrie,et al. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. , 1999, Kidney international.
[15] D. Rolla,et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] A. Covic,et al. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. , 1997, Nephron.
[17] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[18] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[19] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[20] E. Slatopolsky,et al. Noncalcemic analogs of vitamin D , 1994 .
[21] L. Hunt,et al. Comparative mortality from cardiovascular disease in patients with chronic renal failure. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[22] E. Paoletti,et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. , 1993, Kidney international.
[23] Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] A. Sniderman,et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. , 1989, Kidney international.
[25] A. Sniderman,et al. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. , 1989, The American journal of cardiology.
[26] P. Degoulet,et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. , 1982, Nephron.